Contact Information

Available for logged-in reporters only

Newswise LOUISVILLE, Ky. William Tse, M.D., associate professor of medicine and eminent scholar in hematologic malignancies research at the Mary Babb Randolph Cancer Center at West Virginia University, has been named the new director of Bone Marrow Transplantation at the University of Louisville James Graham Brown Cancer Center, a part of KentuckyOne Health. Tse will join UofL Nov. 1.

Tse will hold the Marion F. Beard Endowed Chair in Hematology Research at UofL and become a member of the cancer centers Developmental Biology Program.

Dr. Tse is emerging as one of the thought leaders in bone marrow transplantation, said Donald Miller, M.D., Ph.D., director of the JGBCC. He has trained and worked at several of the leading blood cancer programs in the nation. We look forward to his leading our program at UofL.

Tse has been at West Virginia since 2009, where he also is the co-leader the Osborn Hematologic Malignancies Program. Prior to joining West Virginia, Tse was on the faculty at the University of Colorado Denver, where he was the director of translational research program for bone marrow transplantation and hematologic malignancies. He also previously was with Case Western Reserve University and the Fred Hutchinson Cancer Research Center/University of Washington Medical Center.

Tse is active in national organizations, serving in several capacities with the American Society of Hematology, including section chair for the annual meetings Oncogene Section and bone marrow transplantation outcome section, as well as the American Society of Clinical Oncology as an annual meeting abstract reviewer and the section chair on geriatric oncology. Tse also serves leadership roles on several editorial boards including as the senior editor of the American Journal of Blood Research, stem cell biomarkers section editor for Biomarker Research, senior editor of the American Journal of Stem Cells and the academic editor of PLoS One.

A graduate of the Sun Yat-Sen University School of Medicine in Guangzhou, Guangdong, in China, he did a thoracic surgical oncology residency at Sun Yat-Sen University Cancer Center in Guangzhou before completing postdoctoral research fellowships in medical biophysics, immunology and cancer at the Princess Margaret Hospital/Ontario Cancer Institute and the Hospital for Sick Children in Ontario, Canada. He completed clinical pathology and internal medicine residencies at North Shore-Long Island Jewish Hospital before undertaking a senior medical fellowship in clinical research and medical oncology divisions at the Fred Hutchinson Cancer Research Center at the University of Washington Medical Center.

Follow this link:
Tse Named Director of Bone Marrow Transplantation Division at University of Louisville

Xia Jie.

Medical entrepreneur Xia Jie, whose company Health 100 owns the largest chain of health clinics in China, plans to open overseas facilities to cater for wealthy clients.

That could result in an investment of about $20 million in a regenerative treatment centre in the resort, making it a Mecca for health tourism and athlete injury rehabilitation.

''We're now negotiating with the local medical teams,'' Mr Xia said yesterday through an interpreter while on a four-day fact-finding mission to Queenstown.

''Health 100 really wants to find beautiful cities around the world to take Chinese patients to and Queenstown is one of them.

''The vision is to bring the very high-end customers to have special treatment which is not carried out elsewhere in the world,'' he said.

Health 100 would invest with existing firms Queenstown Regenerative Medicine (QRM), run by Marcelle Noble, and the Queenstown Skin Institute.

Both have small premises at Remarkables Park in Frankton.

Queenstown Skin Institute director Dr Hans Raetz said Mr Xia had indicated plans for a much larger centre, with sites in Remarkables Park, Jacks Point or the Five Mile development off Frankton Ladies Mile already earmarked.

''The size depends on Mr Xia, but we've been talking between $10 million and $20 million.

Read more from the original source:
Stem cell centre proposed for resort

When a child became ill, Jim Pattison was one of many who stepped up as a potential bone marrow donor.

Herald photo by Jodi Schellenberg

Jim Pattison was given two paperweights for his stem cell donation. He decided to become a donor in 1996, but was not a match until after 2010.

In 1996, Pattison was one of many who went on the bone marrow transplant list to help a one and a half year old child who was diagnosed with acute myeloid leukemia. The organizers of the donor drive expected maybe 50 people to show up and were shocked by the close to 400 who attended.

Sadly, the family didnt find a match and the girl died, but Pattison decided to stay on the registry.

They asked if I wanted to stay on and my answer was that if I would do it for Abigail I would do it for anybody, he said.

Throughout the years, Pattison was asked to test for more markers to see if he would be a match for someone else. He did his last test in 2010 and heard back a short time later with the news he was a match.

Pattison was chosen for a peripheral stem cell donation, which is different from a bone marrow transplant because it is less invasive.

I first went to where the stem cells are collected and had a physical, he explained. They sent me back with some drugs that I had to have injected here, that stimulate the stem cells to grow. I had four injections before I went.

They were looking to make sure I had a high enough level of stem cells to make the donation, he added.

More:
Local man shares his story of stem cell donation

A teenager who gave stem cells to save the life of a stranger is backing a national campaign to find more donors.

In June, Celyn Evans, 17, became one of the youngest people in the UK to donate stem cells.

The Colchester Royal Grammar School sixth-form student is supporting Anthony Nolans Save a Life at 16 campaign.

The charity wants HMRC to include details about stem cell donation when it writes to teens with their National Insurance numbers ahead of their 16th birthday.

Celyn, of West Mersea, said: You often hear that young people are self absorbed and not interested in helping others, but I think thats wrong.

People just need to be made aware of how they can help. That is why I am supporting this campaign.

Celyn joined the bone marrow donor register last September when his brothers friend developed leukaemia.

He was not able to help the family friend, but in February, Anthony Nolan contacted him to say he was a possible match for another patient in need of a potentially life-saving transplant.

Celyn agreed to donate and, after a series of check-ups, made the donation in London in June.

Like 90 per cent of donors, he gave his stem cells through a simple, outpatient process similar to giving blood.

Read the original:
Colchester teen becomes one of the UK's youngest stem cell donors

Celyn Evans, 17, from Colchester, has donated stem cells to save the life of a complete stranger. Pictured with the stem cells.

Monday, September 22, 2014 10:49 AM

A selfless teenager from Colchester who donated stem cells to a stranger is backing a campaign to help find more young heroes.

To send a link to this page to a friend, you must be logged in.

In June Celyn Evans, 17, became one of the youngest such donors in the UK.

He was contacted by the Anthony Nolan Trust as a possible match after joining the bone marrow register last September when his brothers friend developed leukaemia.

Now he is supporting Anthony Nolans Save A Life At 16 campaign, calling on HMRC to include details about stem cell donation when it writes to people with their National Insurance number ahead of their 16th birthday.

Celyn said: You often hear that young people are self absorbed and not interested in helping others, but I think thats wrong. People just need to be made aware of how they can help.

Its a very simple process, and I am surprised more people dont do it. But I think its just down to people knowing about it, which is where Anthony Nolans idea comes in.

For more information or to join the register visit the Anthony Nolan Trust website.

Visit link:
Colchester: Selfless teen stem cell donor Celyn Evans backs campaign to find more young heroes

Company plans for the future of stem cell use

by Samantha Schmieder

Staff Writer

Next Healthcare Inc. of Germantown recently launched a partnership with Arizona Cardinals wide reciever Larry Fitzgerald to promote its newest venture, CelBank Pro to other professional athletes.

Next Healthcares CelBank is the collection of cell samples and storage of their blood, skin or stem cells to be used in the future. Stem cells are unspecialized cells that are able to renew themselves through cell division and can be scientifically manipulated to become another type of cell with a more specialized function. They offer hope to provide new ways to fight disease or injuries, according to the National Institutes of Health.

Essentially we are in the business of banking cells for people, Vin Singh, the founder and CEO of Next Healthcare, said.

While CelBank is geared toward anyone interested in using their own cells later in their life, CelBank Pro is geared toward sports players who are very likely to get injured or just worn down during their career.

Skin cells and stem cells are stored at a healthy time at someones life for later use in regenerative medicine, Singh said.

In 2006 and 2007, Singh, who lives in Boyds, heard about a method in Japan that was able to turn adult skin cells into stem cells. Singh decided to build Next Healthcare around these induced pluripotent stem cells, or iPS cells.

For me that was the real spark. I heard about that and thought, Wow, this is an amazing, revolutionary breakthrough, Singh said. Thats where the idea came from, what can we do with that technology. There has to be something that I can do for consumers to give them an advantage.

Continue reading here:
Germantown

Company plans for the future of stem cell use

by Samantha Schmieder

Staff Writer

Next Healthcare Inc. of Germantown recently launched a partnership with Arizona Cardinals wide reciever Larry Fitzgerald to promote its newest venture, CelBank Pro to other professional athletes.

Next Healthcares CelBank is the collection of cell samples and storage of their blood, skin or stem cells to be used in the future. Stem cells are unspecialized cells that are able to renew themselves through cell division and can be scientifically manipulated to become another type of cell with a more specialized function. They offer hope to provide new ways to fight disease or injuries, according to the National Institutes of Health.

Essentially we are in the business of banking cells for people, Vin Singh, the founder and CEO of Next Healthcare, said.

While CelBank is geared toward anyone interested in using their own cells later in their life, CelBank Pro is geared toward sports players who are very likely to get injured or just worn down during their career.

Skin cells and stem cells are stored at a healthy time at someones life for later use in regenerative medicine, Singh said.

In 2006 and 2007, Singh, who lives in Boyds, heard about a method in Japan that was able to turn adult skin cells into stem cells. Singh decided to build Next Healthcare around these induced pluripotent stem cells, or iPS cells.

For me that was the real spark. I heard about that and thought, Wow, this is an amazing, revolutionary breakthrough, Singh said. Thats where the idea came from, what can we do with that technology. There has to be something that I can do for consumers to give them an advantage.

See the rest here:
Germantown's Next Healthcare pairs with NFL player

(PRWEB UK) 22 September 2014

BioKidz is a simple concept which aims to engage children in the importance of stem cell medicine. Aimed at an audience of 4-9 year olds, the company now aims to use it in the 21 countries in which it operates.

BioEden has been invited to speak with parents and teachers later this month, as the BioKidz site aims to be a good source of scientific information for primary school teachers.

The BioEden proposition is very simple one: harvest the stem cells from a naturally shed baby tooth, store the viable cells for future therapeutic use, and guarantee that the cells will be available when needed.

As stem cell medicine is now becoming commonplace, it is important that there is a stem cell match when needed. The easiest way to do this is by harvesting and storing one's own cells, and there is no easier way than from naturally shed teeth.

The company admits that they could be putting the ordinary tooth fairy out of business, but they hasten to add that BioKidz have their own hero in the form of a Super Tooth Fairy who works within their own stem cell laboratories.

Children can meet BioEden the Super Tooth Fairy by visiting http://www.bioeden.com.

Continue reading here:
BioKidz: the Children of the Stem Cell Revolution to go Global

About three million Briton currently suffer osteoporosis which is affected by a number factors such as genes, a lack of exercise and poor diet and results in about 60,000 hip, 50,000 wrist and 120,000 spinal fractures every year, according to the National Osteoporosis Society, costing about 1.7 billion in health and social care.

Dr Ifty Ahmed, a researcher at Nottingham University, said his team wanted to provide a preventative treatment, strengthening the bones of those at risk before they suffered a fracture.

Speaking at the Regener8 conference on regenerative medicine, in Leeds last week, he said: Our aim would be to use screening to spot people who are at risk, then strengthen their bones before they get fractures.

It means that rather than waiting until people have a fall and break something, we would try to stop that ever happening, along with the consequences, loss of independence, surgery and secondary illnesses.

Previous attempts have been made to find ways of strengthening thinning bones but the difficulties of protecting the fragile stem cells has meant no such treatments have yet been developed.

Dr Ahmeds team hope to overcome this problem by puncturing the tiny hollow spheres of calcium phosphate allowing the stem cells to migrate inside them where they are protected.

The experimental treatment has not yet been trialled on humans.

It would involve extracting stem cells from a patients bone marrow and mixing them with the microspheres before injecting the paste into the vulnerable bones.

Dr Ahmed said: "If it works, this kind of treatment could be done in a day.

Until now the team have been funded by the Engineering and Physical Sciences Research Council but they are now looking for a commercial partner.

Read the rest here:
Bone paste could provide treatment for ostoeporosis

Frankfurt, Germany (PRWEB) September 19, 2014

The Translational Research Institute TRI Medical announced today that its new ND Infusion Catheter is being used in a first-in-man procedure at the University of Frankfurt.

The study commenced on September 4th, 2014 at the University of Frankfurt, Department of Cardiology. The use of the new catheter demonstrated a number of advancements in the delivery of regenerative therapeutics, commonly known as stem cells. We are at the forefront of revolutionizing stem cell delivery to the heart, TRI Medicals Nabil Dib, MD, Msc, offered. The ND Infusion Catheter provides safety and potential efficacy. The catheter also reduces the procedure time to approximately 15 minutes; enabling patients to walk and resume activities in about 2 hours, Dr. Dib continued.

The renowned German Cardiology Center at the University of Frankfurt has extensive experience with the development of cardiac cell-based regenerative therapeutics. Prof. Dr. Andreas M. Zeiher, Chairman of the Department of Cardiology at the University of Frankfurt stated The catheter provides the unique potential to precisely regulate coronary blood flow, while administering cells directly into the heart thus improving safety and potentially efficacy. The innovative design of the catheter's balloon accommodates different vessel sizes, avoiding the need to use multiple catheters, reducing potential risks associated with exchanging the balloon catheter when treating different coronary arteries in an individual patient.

Prior to the first-in-man procedure, extensive cell compatibility testing of bone marrow derived cells with the ND Infusion Catheter revealed that the catheter preserved cell viability and functionality, Stefanie Dimmeler, PhD and Director of the Institute of Cardiovascular Regeneration, Centre of Molecular Medicine stated. The testing proved that the cells are compatible with the ND Infusion Catheter. We see this as potential improvements in safety and clinical outcomes related to cell function and efficacy in patients, Dr. Dimmeler offered.

Safety was top-of-mind when we initiated the first-in-man procedure in Frankfurt. We are elated to report that the procedures outcomes were successful, Dr. Dib stated. Earlier studies revealed that the ND Infusion Catheter reduces cellular clumping, preserves cell viability, improves dispersion and reduces radial forces on the vessel walls during balloon inflation; which collectively might improve patient safety and clinical outcomes.

TRI Medicals Ron Anson, Vice President of Business Development shared The catheters unique design features provide physicians with a valuable new tool in the delivery of specified fluids such as stem cells. We expect to see significant growth in the stem cell research marketplace for the new, state-of-the-art ND Infusion Catheter.

ABOUT TRI Medical TRI Medical is a privately held, medical device development company. TRI Medical is dedicated to providing a pathway to regulatory approval that is efficient, predictable and cost effective.

#####

Media inquiries regarding TRI Medical, its capabilities and for additional information regarding the ND Infusion Catheter contact: DeAnn Dana Phone: 480.309.2884 Email: DDana(at)TRImedical.com TRI Medical website: http://www.trimedical.com

Go here to read the rest:
First-in-man procedure utilizes a new method of stem cell delivery

Two men who changed each others lives forever by being on the giving and receiving ends of a bone marrow transplant met for the first time today and had their first chance to say, Thank you, face-to-face.

Thank you so much, Joe Yannantuono, 33, said to his bone marrow donor, Justin Jenkins, 35, as he embraced him in a hug in a live, emotional meeting on Good Morning America.

Yannantuono, not very long ago, was waging a two-year long battle for his life against stage 4 lymphoma.

WATCH: Robin Roberts Celebrates 1-Year Anniversary of Bone Marrow Transplant

Toddler Meets Life-Saving Bone Marrow Donor

As his wife, Christine Buono, and his 4-year-old son, JJ Yannantuono, stood by his side, the family, from Staten Island, N.Y., got the unbelievable news that a man in Texas, a stranger, was a rare 10 for 10 genetic bone marrow match.

That stranger in Texas, Jenkins, of Dallas, had registered to be a bone marrow donor by chance 15 years ago when he was 21-years-old and donated blood because they were offering free snacks.

Soon after Jenkins was found to be a match, his stem cells were transported by airplane to New York and transplanted into Yannatuonos body in December 2012 at Memorial Sloan Kettering Cancer Center.

For more than one year after the successful transplant, Yannantuono had no idea whose cells he was now carrying in his body.

As Yannantuono was rebuilding his life, Jenkins life was thrown a tragic curveball. His mother, who raised him on her own and had been a big part of his donation journey, was killed in a car crash.

Read the rest here:
Bone Marrow Recipient Meets Donor Who Saved His Life

Investigators from the Institute for Research in Immunology and Cancer (IRIC) at the Universit de Montral have just published, in the journal Science, the announcement of the discovery of a new molecule, the first of its kind, which allows for the multiplication of stem cells in a unit of cord blood. Umbilical cord stem cells are used for transplants aimed at curing a number of blood-related diseases, including leukemia, myeloma and lymphoma. For many patients this therapy comprises a treatment of last resort.

Directed by Dr. Guy Sauvageau, principal investigator at IRIC and hematologist at the Maisonneuve-Rosemont Hospital, the research has the potential to multiply by 10 the number of cord blood units available for a transplant in humans. In addition, it will considerably reduce the complications associated with stem cell transplantation. And it will be particularly useful for non-Caucasian patients for whom compatible donors are difficult to identify.

A clinical study using this molecule, named UM171 in honor of the Universit de Montral, and a new type of bioreactor developed for stem culture in collaboration with the University of Toronto will be initiated in December 2014 at the Maisonneuve-Rosemont Hospital.

According to Dr. Guy Sauvageau, "This new molecule, combined with the new bioreactor technology, will allow thousands of patients around the world access to a safer stem cell transplant. Considering that many patients currently cannot benefit from a stem cell transplant for lack of matching donors, this discovery looks to be highly promising for the treatment of various types of cancer."

The Centre of Excellence for Cellular Therapy at the Maisonneuve-Rosemont Hospital will serve as production unit for these stem cells, and grafts will then be distributed to patients in Montreal, Quebec City and Vancouver for this first Canadian clinical study. Tangible results should be available one year later, that is, in December 2015. The significance of this new discovery is such that over time, conclusive clinical results could revolutionize the treatment of leukemia and other blood-related illnesses.

"These extraordinary advances result from the efforts of a remarkable team that includes extremely gifted students and postdoctoral investigators working in the IRIC laboratories," adds Dr. Guy Sauvageau. "Among them, the first authors of this publication: Iman Fars, doctoral student, and Jalila Chagraoui, research officer, along with the professionals in IRIC's medical chemistry core facility under the direction of Anne Marinier, who optimized the therapeutic properties of this new molecule."

Context

Umbilical cord blood from newborn children is an excellent source of hematopoietic stem cells for stem cell transplants, since their immune system is still immature and the stem cells have a lower probability of inducing an adverse immune reaction in the recipient.

Furthermore, it is not necessary for the immunological compatibility between donor and recipient to be perfect, unlike in a bone marrow transplant. However, in most cases the number of stem cells obtained from an umbilical cord is much too low for treating an adult, and its use is confined above all to the treatment of children. With the new molecule UM171 it will be possible to multiply stem cells in culture and to produce enough of them to treat adults, especially those who are not Caucasian, and who because of the lack of donors have limited access to transplants.

Collaborators from the Maisonneuve-Rosemont Hospital, the British Columbia Cancer Agency, the Ontario Cancer Institute and the Fred Hutchison Cancer Research Center also played an important role in evaluating the biological properties of this new molecule, and those from the University of Toronto in developing the bioreactor.

Read more:
New molecule allows for up to 10-fold increase in stem cell transplants

Cellular therapeutics -- using intact cells to treat and cure disease -- is a hugely promising new approach in medicine but it is hindered by the inability of doctors and scientists to effectively track the movements, destination and persistence of these cells in patients without resorting to invasive procedures, like tissue sampling.

In a paper published September 17 in the online journal Magnetic Resonance in Medicine, researchers at the University of California, San Diego School of Medicine, University of Pittsburgh and elsewhere describe the first human tests of using a perfluorocarbon (PFC) tracer in combination with non-invasive magnetic resonance imaging (MRI) to track therapeutic immune cells injected into patients with colorectal cancer.

"Initially, we see this technique used for clinical trials that involve tests of new cell therapies," said first author Eric T. Ahrens, PhD, professor in the Department of Radiology at UC San Diego. "Clinical development of cell therapies can be accelerated by providing feedback regarding cell motility, optimal delivery routes, individual therapeutic doses and engraftment success."

Currently, there is no accepted way to image cells in the human body that covers a broad range of cell types and diseases. Earlier techniques have used metal ion-based vascular MRI contrast agents and radioisotopes. The former have proven difficult to differentiate in vivo; the latter raise concerns about radiation toxicity and do not provide the anatomical detail available with MRIs.

"This is the first human PFC cell tracking agent, which is a new way to do MRI cell tracking," said Ahrens. "It's the first example of a clinical MRI agent designed specifically for cell tracking."

Researchers used a PFC tracer agent and an MRI technique that directly detects fluorine atoms in labeled cells. Fluorine atoms naturally occur in extremely low concentrations in the body, making it easier to observe cells labeled with fluorine using MRI. In this case, the modified and labeled dendritic cells -- potent stimulators of the immune system -- were first prepared from white blood cells extracted from the patient. The cells were then injected into patients with stage 4 metastatic colorectal cancer to stimulate an anti-cancer T-cell immune response.

The published study did not assess the efficacy of the cell therapy, but rather the ability of researchers to detect the labeled cells and monitor what happened to them. Ahrens said the technique worked as expected, with the surprising finding that only half of the delivered cell vaccine remained at the inoculation site after 24 hours.

"The imaging agent technology has been to shown to be able to tag any cell type that is of interest," Ahrens said. "It is a platform imaging technology for a wide range of diseases and applications," which might also speed development of relevant therapies.

"Non-invasive cell tracking may help lower regulatory barriers," Ahrens explained. "For example, new stem cell therapies can be slow to obtain regulatory approvals in part because it is difficult, if not impossible, with current approaches to verify survival and location of transplanted cells. And cell therapy trials generally have a high cost per patient. Tools that allow the investigator to gain a 'richer' data set from individual patients mean it may be possible to reduce patient numbers enrolled in a trial, thus reducing total trial cost."

Story Source:

See original here:
Better way to track emerging cell therapies using MRIs

Stem Cell Therapy | why no more news about embryonic stem cells
http://www.arthritistreatmentcenter.com Is embryonic stem cell research passe? Next How come no more news about embryonic stem cells? Embryonic stem cells come from human embryos and these...

By: Nathan Wei

More:
Stem Cell Therapy | why no more news about embryonic stem cells - Video

Stem Cell Therapy Professional Football Player
James Lee a Professional Football player is back in action thanks to stem cell therapy and Dr. Dennis M. Lox MD. Dr. Lox | http://www.drloxstemcells.com | (844) 440...

By: Dr. Lox

Go here to read the rest:
Stem Cell Therapy Professional Football Player - Video

9 Global Options Stem Cell Therapy for Parkinson #39;s Disease
Parkinson #39;s disease is a neuromuscular condition that affects millions of people around the world. Uncontrollable movement of the body muscles along with str...

By: placidways

Read more here:
9 Global Options Stem Cell Therapy for Parkinson's Disease - Video

PUBLIC RELEASE DATE:

18-Sep-2014

Contact: Luke Harrison l.harrison.1@bham.ac.uk University of Birmingham @unibirmingham

A key step in understanding the nature of the fight for superiority between mutated genes and normal genes could lead to new therapies to combat leukaemia, say researchers from the University of Birmingham and Newcastle University.

The study, published in Cell Reports, investigated Acute Myeloid Leukaemia to understand why leukemic cells are not able to develop normally into mature blood cells.

Stem cells in the bone marrow generate billions of different blood cells each day. The process resembles a production line with genes acting as regulators to control each step of the blood formation.

Leukaemia arises when the DNA encoding regulators in the stem cells is changed by a mutation. When a mutation occurs in the relevant regulator genes, the finely balanced order of the production line is disrupted with drastic consequences.

A chain reaction occurs, with the function of other regulators in the process being altered. The new cells no longer develop into normal blood cells, but leukemic cells that multiply and begin to take over the body.

Professor Constanze Bonifer, of the University of Birmingham, explained, "This particular leukaemia is characterised by a mutation in a gene that produces a rogue regulator. That is, one that is not normally made and behaves in a different way. The knock-on effect of that one mutation is huge."

The team showed that this aberrant regulator switches off hundreds of other genes, many of them regulators themselves, by using state of the art technology that looks at the activity of all genes within a cell. As a consequence of the drastically altered production line, normal blood formation cannot happen, and leukemic cells are formed.

Go here to see the original:
The war on leukemia: How the battle for cell production could be decisive

Contact Information

Available for logged-in reporters only

Newswise Investigators from the Institute for Research in Immunology and Cancer (IRIC) at the Universit de Montral have just published, in the prestigious magazine Science, the announcement of the discovery of a new molecule, the first of its kind, which allows for the multiplication of stem cells in a unit of cord blood. Umbilical cord stem cells are used for transplants aimed at curing a number of blood-related diseases, including leukemia, myeloma and lymphoma. For many patients this therapy comprises a treatment of last resort.

Directed by Dr. Guy Sauvageau, principal investigator at IRIC and hematologist at the Maisonneuve-Rosemont Hospital, this world breakthrough has the potential to multiply by 10 the number of cord blood units available for a transplant in humans. In addition, it will considerably reduce the complications associated with stem cell transplantation. And it will be particularly useful for non-Caucasian patients for whom compatible donors are difficult to identify.

A clinical study using this molecule, named UM171 in honor of the Universit de Montral, and a new type of bioreactor developed for stem culture in collaboration with the University of Toronto will be initiated in December 2014 at the Maisonneuve-Rosemont Hospital.

According to Dr. Guy Sauvageau, This new molecule, combined with the new bioreactor technology, will allow thousands of patients around the world access to a safer stem cell transplant. Considering that many patients currently cannot benefit from a stem cell transplant for lack of matching donors, this discovery looks to be highly promising for the treatment of various types of cancer.

The Centre of Excellence for Cellular Therapy at the Maisonneuve-Rosemont Hospital will serve as production unit for these stem cells, and grafts will then be distributed to patients in Montreal, Quebec City and Vancouver for this first Canadian clinical study. Tangible results should be available one year later, that is, in December 2015. The significance of this new discovery is such that over time, conclusive clinical results could revolutionize the treatment of leukemia and other blood-related illnesses.

These extraordinary advances result from the efforts of a remarkable team that includes extremely gifted students and postdoctoral investigators working in the IRIC laboratories, adds Dr. Guy Sauvageau. Among them, the first authors of this publication: Iman Fars, doctoral student, and Jalila Chagraoui, research officer, along with the professionals in IRICs medical chemistry core facility under the direction of Anne Marinier, who optimized the therapeutic properties of this new molecule.

Context

Umbilical cord blood from newborn children is an excellent source of hematopoietic stem cells for stem cell transplants, since their immune system is still immature and the stem cells have a lower probability of inducing an adverse immune reaction in the recipient.

See more here:
World Breakthrough: A New Molecule Allows for an Increase in Stem Cell Transplants

Contact Information

Available for logged-in reporters only

Newswise NEW YORK, September 18, 2014 Scientists at NYU Langone Medical Center have found a way to boost dramatically the efficiency of the process for turning adult cells into so-called pluripotent stem cells by combining three well-known compounds, including vitamin C.

Using the new technique in mice, the researchers increased the number of stem cells obtained from adult skin cells by more than 20-fold compared with the standard method. They say their technique is efficient and reliable, and thus should generally accelerate research aimed at using stem cells to generate virtually any tissue. Stem cells are immature or uncommitted cells that are theoretically capable of becoming any cell type.

This big boost in efficiency gives us an opportunity now to study stem cell programming mechanisms at high resolution, says Matthias Stadtfeld, PhD, assistant professor of cell biology and a member of the Skirball Institute of Biomolecular Medicine and the Helen L. and Martin S. Kimmel Center for Stem Cell Biology at NYU Langone Medical Center, who led the research.

This is a very exciting advance, says Ruth Lehmann, PhD, director of the Kimmel Center for Stem Cell Biology and the Skirball Institute at NYU Langone and chair of the Department of Cell Biology. The new technology developed by the Stadtfeld lab to reprogram differentiated cells efficiently and effectively brings the prospect of stem cell technology for safe use in regenerative medicine ever so much closer."

The standard method for reprogramming skin, blood, or other tissue-specific cell types into induced pluripotent stem cells (iPSCs) was reported in 2006 by the laboratory of Kyoto Universitys Shinya Yamanaka, who later won a Nobel Prize for the achievement. The method involves the artificial expression of four key genes dubbed OKSM (for Oct4, Klf4, Sox2 and myc) whose collective activity slowly prods cells into an immature state much like that of an early embryonic cell.

In principle, one could take a sample of cells from a person, induce the cells to become iPSCs, then multiply the iPSCs in a lab dish and stimulate them to mature towards desired adult cell types such as blood, brain or heartwhich then could be used to replace injured or diseased tissue in that same individual.

But there are many formidable technical obstacles, among which is the low efficiency of currently used protocols. Converting most cell types into stable iPSCs occurs at rates of 1 percent or less, and the process can take weeks.

Researchers throughout the world have been searching for ways to boost this efficiency, and in some cases have reported significant gains. These procedures, however, often alter vital cellular genes, which may cause problems for potential therapies. For the new study, reported online today in Stem Cell Reports, Dr. Stadtfeld and his laboratory team decided to take a less invasive approach and investigate chemical compounds that transiently modulate enzymes that are present in most cells. We especially wanted to know if these compounds could be combined to obtain stem cells at high efficiency, Dr. Stadtfeld says.

Go here to read the rest:
NYU Langone Scientists Report Reliable and Highly Efficient Method for Making Stem Cells

11 hours ago A new method resulted in a colony of stem cells, glowing green, derived from one adult immune cell. Credit: Laboratory of Matthias Stadtfeld at NYU Langone Medical center

Scientists at NYU Langone Medical Center have found a way to boost dramatically the efficiency of the process for turning adult cells into so-called pluripotent stem cells by combining three well-known compounds, including vitamin C. Using the new technique in mice, the researchers increased the number of stem cells obtained from adult skin cells by more than 20-fold compared with the standard method. They say their technique is efficient and reliable, and thus should generally accelerate research aimed at using stem cells to generate virtually any tissue. Stem cells are immature or uncommitted cells that are theoretically capable of becoming any cell type.

"This big boost in efficiency gives us an opportunity now to study stem cell programming mechanisms at high resolution," says Matthias Stadtfeld, PhD, assistant professor of cell biology and a member of the Skirball Institute of Biomolecular Medicine and the Helen L. and Martin S. Kimmel Center for Stem Cell Biology at NYU Langone Medical Center, who led the research.

"This is a very exciting advance," says Ruth Lehmann, PhD, director of the Kimmel Center for Stem Cell Biology and the Skirball Institute at NYU Langone and chair of the Department of Cell Biology. "The new technology developed by the Stadtfeld lab to reprogram differentiated cells efficiently and effectively brings the prospect of stem cell technology for safe use in regenerative medicine ever so much closer."

The standard method for reprogramming skin, blood, or other tissue-specific cell types into "induced pluripotent stem cells" (iPSCs) was reported in 2006 by the laboratory of Kyoto University's Shinya Yamanaka, who later won a Nobel Prize for the achievement. The method involves the artificial expression of four key genes dubbed OKSM (for Oct4, Klf4, Sox2 and myc) whose collective activity slowly prods cells into an immature state much like that of an early embryonic cell.

In principle, one could take a sample of cells from a person, induce the cells to become iPSCs, then multiply the iPSCs in a lab dish and stimulate them to mature towards desired adult cell types such as blood, brain or heartwhich then could be used to replace injured or diseased tissue in that same individual.

But there are many formidable technical obstacles, among which is the low efficiency of currently used protocols. Converting most cell types into stable iPSCs occurs at rates of 1 percent or less, and the process can take weeks.

Researchers throughout the world have been searching for ways to boost this efficiency, and in some cases have reported significant gains. These procedures, however, often alter vital cellular genes, which may cause problems for potential therapies. For the new study, reported online today in Stem Cell Reports, Dr. Stadtfeld and his laboratory team decided to take a less invasive approach and investigate chemical compounds that transiently modulate enzymes that are present in most cells. "We especially wanted to know if these compounds could be combined to obtain stem cells at high efficiency," Dr. Stadtfeld says.

Two of these compounds influence well known signaling pathways, called Wnt and TGF-, which regulate multiple growth-related processes in cells. The third is vitamin C (also known as ascorbic acid). Best known as a powerful antioxidant, the vitamin was recently discovered to assist in iPSC induction by activating enzymes that remodel chromatinthe spiral scaffold for DNAto regulate gene expression.

Simon Vidal, a graduate student in the Stadtfeld lab, and Bhishma Amlani, a postdoctoral researcher, looked first at mouse skin fibroblasts, the most common cell type used for iPSC research. Adding to fibroblasts engineered to express OKSM either vitamin C, a compound to activate Wnt signaling, or a compound to inhibit TGF- signaling increased iPSC-induction efficiency weakly to about 1% after a week of cell culture. Combining any two worked a bit better. But combining all three brought the efficiency to about 80 percent in the same period of time.

More here:
Team reports reliable, highly efficient method for making stem cells